Medical Oncology ( IF 2.8 ) Pub Date : 2023-05-16 , DOI: 10.1007/s12032-023-02045-2 Neha Bhatia 1 , Suresh Thareja 1
|
Elacestrant (RAD-1901), a selective estrogen receptor degrader, was approved by USFDA on January 27, 2023, for the treatment of breast cancer. It has been developed by Menarini Group under the brand name Orserdu®. Elacestrant showed anticancer activity both in vitro and in vivo in ER+ HER2-positive breast cancer models. The present review delebrates the development stages of Elacestrant, with its medicinal chemistry, synthesis, mechanism of action, and pharmacokinetic studies. Clinical data and safety profile has also been discussed, including data from randomized trials.
中文翻译：
Elacestrant：一种新的 FDA 批准的用于治疗乳腺癌的 SERD
Elacestrant (RAD-1901) 是一种选择性雌激素受体降解剂，于 2023 年 1 月 27 日获得 USFDA 批准用于治疗乳腺癌。它由美纳里尼集团以 Orserdu® 品牌开发。Elacestrant 在 ER+ HER2 阳性乳腺癌模型中显示出体外和体内的抗癌活性。本综述阐述了 Elacestrant 的开发阶段，包括其药物化学、合成、作用机制和药代动力学研究。还讨论了临床数据和安全性概况，包括来自随机试验的数据。
京公网安备 11010802027423号